Clinical Trial Update: A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of AP-306 in patients with hyperphosphatemia due to chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• AP-306

Snippet

Sponsor: Alebund Pharmaceuticals | Conditions: Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Status: COMPLETED